Member
Glycos Biomedical Ltd
We are UK/US entity with a team based in Maryland and North Carolina comprising an expert team that has linked triggers to disease states including TBI and acute injuries associated with radiation, acute lung injury and infection.
Industries
Pharmaceutical
Medical device
Nr. of Employees
small (1-50)
Glycos Biomedical Ltd
6th Floor 2 London Wall Place, London, United Kingdom, EC2Y 5AU
Patents
Method for characterizing melting transition and crystallization in a semicrystalline polymer
2026-05-12 • US-12625073-B2
View DetailsOptical device, spectroscopic device, and spectroscopic method
2026-05-12 • US-12625068-B2
View DetailsComposition for culturing brain organoid based on decellularized brain matrix and method for preparing same
2026-05-12 • US-12624340-B2
View Details
Method for characterizing melting transition and crystallization in a semicrystalline polymer
2026-05-12 • US-12625073-B2
View DetailsOptical device, spectroscopic device, and spectroscopic method
2026-05-12 • US-12625068-B2
View DetailsComposition for culturing brain organoid based on decellularized brain matrix and method for preparing same
2026-05-12 • US-12624340-B2
View DetailsProducts
GBM-1511
GBM-1511 acts on the disease pathways for TBI and other triggers for acute injury
GBM-1511
GBM-1511 acts on the disease pathways for TBI and other triggers for acute injury
Key People
Dr Paul Bhogal
Director
Dr Muhammad Ahmad
Director
Dr Ounali Jaffer
Director
Mr Elliott Pauli
Programme Manager
Dr Paul Bhogal
Director
Dr Muhammad Ahmad
Director
Dr Ounali Jaffer
Director
Mr Elliott Pauli
Programme Manager